By a News Reporter-Staff News Editor at China Weekly News -- Current study results on Biotechnology have been published. According to news reporting from Seoul, South Korea, by VerticalNews journalists, research stated, "IntroductionABL1 kinase mutations represent a major mechanism of imatinib resistance in Philadelphia-positive (Ph+) patients. There is a paucity of data on ABL1 kinase mutations in Ph+ patients in Korea."
The news correspondents obtained a quote from the research from the University of Ulsan, "MethodsWe used restriction fragment mass polymorphism (RFMP) analysis to detect ABL1 kinase mutations in blood or bone marrow specimens from 80 Ph+ patients. ResultsFifty-seven patients met the criteria for inadequate molecular response (IMR). ABL1 kinase mutations were found in 2.6% of patients with chronic-phase chronic myelogenous leukemia (CML), 25.0% of accelerated-phase CML, 66.7% of blast-phase CML, and in 58.3% with Ph+ acute lymphoblastic leukemia. Twelve mutations were identified: 7 T315I, 2 E255V, 1 E255K, 1 F359V, and 1 Y253H. The majority of mutation-positive patients showed an unfavorable clinical course and often had an extra Ph or additional chromosomal abnormalities. Mutations were detected in two patients who had very low or absent BCR-ABL1 normalized ratios. ConclusionMutation analysis should be performed in Ph+ patients exhibiting an IMR to imatinib."
According to the news reporters, the research concluded: "RFMP analysis is helpful for revising therapeutic strategies because it can sensitively detect clinically relevant ABL1 kinase mutations with high frequencies."
For more information on this research see: Detection of ABL1 kinase mutations in Philadelphia-positive patients exhibiting an inadequate molecular response using restriction fragment mass polymorphism and its clinical significance: a single-center experience in Korea. International Journal of Laboratory Hematology, 2013;35(6):589-600. International Journal of Laboratory Hematology can be contacted at: Wiley-Blackwell, 111 River St, Hoboken 07030-5774, NJ, USA. (Wiley-Blackwell - www.wiley.com/; International Journal of Laboratory Hematology - onlinelibrary.wiley.com/journal/10.1111/(ISSN)1751-553X)
Our news journalists report that additional information may be obtained by contacting Y.U. Cho, University of Ulsan, Dept. of Pediat, Coll Med, Seoul 138736, South Korea. Additional authors for this research include S.O. Kim, H.S. Chi, S.J. Park, S. Jang, C.J. Park, E.J. Seo, J.H. Lee, K.H. Lee, H.J. Im, J.J. Seo and S.P. Hong.
Keywords for this news article include: Biotechnology, Seoul, Kinase, South Korea, Enzymes and Coenzymes, Leukemia Gene Therapy, Chronic Myelogenous Leukemia
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC